In vitro Ig‐synthesis and proliferative activity in multiple myeloma are stimulated by different growth factors

Plasma cells isolated from bone marrow (BM) aspirates of 15 patients with active multiple myeloma (MM) were cultured and analysed for in vitro proliferative response and Ig‐synthesis upon stimulation with interleukin‐3 (IL‐3), interleukin‐4 (IL‐4) and interleukin‐6 (IL‐6). The proliferative response, determined as Ki‐67 positivity in concentrated plasma cells, was increased by IL‐6 (Stimulation Index, SI=1.77±0.21 (M±SEM)) but not by IL‐3 or IL‐4. This proliferation could be blocked by anti‐IL‐6. In vitro Igsynthesis was stimulated by IL‐4 (SI = 1.62±0.12 (M±SEM) P<0.05) but not by IL‐6 or IL‐3. This effect was not antagonized by anti‐IL‐6. An inverse correlation was found in this group of patients between the IL‐6 induced stimulation of plasma cell proliferative activity and the IL‐4 induced increase of Ig‐synthesis (P=0.027).

[1]  Charles W. Taylor,et al.  Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms , 1990 .

[2]  D. Norman,et al.  Production of cytokines by bone marrow cells obtained from patients with multiple myeloma , 1989 .

[3]  H. Asaoku,et al.  BSF‐2/IL‐6 does not augment lg secretion but stimulates proliferation in myeloma cells , 1989, American journal of hematology.

[4]  G. Gaidano,et al.  Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma , 1989, The Journal of experimental medicine.

[5]  B. Klein,et al.  Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. , 1989, Blood.

[6]  H. Asaoku,et al.  Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. , 1989, Blood.

[7]  M. King,et al.  Tumor cell heterogeneity in multiple myeloma: antigenic, morphologic, and functional studies of cells from blood and bone marrow. , 1989, Blood.

[8]  C. Morimoto,et al.  Response patterns of purified myeloma cells to hematopoietic growth factors. , 1989, Blood.

[9]  B. Barlogie,et al.  Plasma cell myeloma--new biological insights and advances in therapy. , 1989, Blood.

[10]  H. Asaoku,et al.  Altered cytokine activities are related to the suppression of synthesis of normal immunoglobulin in multiple myeloma , 1989, American journal of hematology.

[11]  M. Jourdan,et al.  Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. , 1989, Blood.

[12]  H. Asaoku,et al.  Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma. , 1988, Blood.

[13]  H. Asaoku,et al.  Separation of human myeloma cells from bone marrow aspirates in multiple myeloma and their proliferation and M-protein secretion in vitro. , 1988, Blood.

[14]  H. Asaoku,et al.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.

[15]  T. Bringman,et al.  Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. , 1987, The New England journal of medicine.

[16]  K. Arai,et al.  B cell growth-promoting activity of recombinant human interleukin 4. , 1987, Journal of immunology.

[17]  W. Paul,et al.  Receptors for B-cell stimulatory factor-1 expressed on cells of haematopoietic lineage , 1987, Nature.

[18]  T. Taniguchi,et al.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin , 1986, Nature.

[19]  K. Arai,et al.  Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell- and T-cell-stimulating activities. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[20]  L. Moretta,et al.  B cell growth factor activity of interferon-gamma. Recombinant human interferon-gamma promotes proliferation of anti-mu-activated human B lymphocytes. , 1986, Journal of immunology.

[21]  C. Smith,et al.  Characterization of a murine lymphokine distinct from interleukin 2 and interleukin 3 (IL-3) possessing a T-cell growth factor activity and a mast-cell growth factor activity that synergizes with IL-3. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. Hirano,et al.  Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Waldmann,et al.  Expression of interleukin 2 receptors on activated human B cells , 1984, The Journal of experimental medicine.

[24]  S. Salmon,et al.  Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. , 1980, Blood.

[25]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[26]  T. Grogan,et al.  Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. , 1990, Blood.

[27]  J. Berenson,et al.  Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. , 1989, Blood.

[28]  K. Ishizaka.  IgE-binding factors and regulation of the IgE antibody response. , 1988, Annual review of immunology.

[29]  T. Kishimoto.  Factors affecting B-cell growth and differentiation. , 1985, Annual review of immunology.